Int J Stomatol ›› 2020, Vol. 47 ›› Issue (1): 43-50.doi: 10.7518/gjkq.2020025
• Oral Medicine • Previous Articles Next Articles
Dong Yunmei,Tao Yan,Zhou Yu(
)
CLC Number:
| [1] | George A, Sreenivasan BS, Sunil S , et al. Potentially malignant disorders of oral cavity[J]. Oral Maxillofac Pathol J, 2011,2(1):95-100. |
| [2] | 石佳鸿, 周红梅 . 口腔潜在恶性病变的无创筛查及管理[J]. 中国实用口腔科杂志, 2015,8(12):705-708. |
| Shi JH, Zhou HM . Noninvasive screening and intervention of oral potential malignant disorders[J]. Chin J Pract Stomatol, 2015,8(12):705-708. | |
| [3] | 李晨曦, 施琳俊, 唐国瑶 . 无创筛查技术早期诊断口腔潜在恶性病患癌变的研究进展[J]. 临床口腔医学杂志, 2017,33(6):381-383. |
| Li CX, Shi LJ, Tang GY . Advances in non-invasive screening techniques for early diagnosis of canceration in oral potential malignant diseases[J]. J Clin Stomatol, 2017,33(6):381-383. | |
| [4] | Scully C . Serum β2 microglobulin in oral malignancy and premalignancy[J]. J Oral Pathol Med, 1981,10(5):354-357. |
| [5] | Singh AP, Kumar N, Raju MS , et al. Estimation of serum β2-microglobulin in potentially malignant disorders and squamous cell carcinoma of the oral cavity: a clinicopathological study[J]. Dent Res J (Isfahan), 2014,11(1):109-113. |
| [6] | Kadam CY, Katkam RV, Suryakar AN , et al. Biochemical markers in oral cancer[J]. Biomed Res, 2011,22(1):76-80. |
| [7] | Chen CH, Su CY, Chien CY , et al. Overexpression of β2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion[J]. Br J Cancer, 2008,99(9):1453-1461. |
| [8] | Bouquot J, Suarez P, Nadarajah V . Oral precancer and early detection in the dental office- review of new technologies[J]. J Implant Advanced Clin Dent, 2010,2(3):47-63. |
| [9] | Saddiwal R, Hebbale M, Sane VD , et al. Estimation of serum beta 2-microglobulin levels in individuals exposed to carcinogens: clinical study in Indian population[J]. J Maxillofac Oral Surg, 2017,16(1):53-57. |
| [10] | Sanjay RB, Madhavi RB, Shyam NDVN . Tumor markers in oral neoplasia[J]. Indian J Dent Adv, 2010,2(1):103-114. |
| [11] | Rhodus NL.Oralcancer and precancer: improving outcomes[J]. Compend Contin Educ Dent, 2009, 30(8):486-488, 490-494, 496-498, 504, 520. |
| [12] | Silvia CR, Vasudevan DM, Prabhu KS . Alteration of serum beta 2-microglobulin in oral carcinoma[J]. Indian J Clin Biochem, 2002,17(2):104-107. |
| [13] | Mazher N, Iqbal Z, Aslam N , et al. Beta-2-microglobulin as a marker of extent of disease in non-Hodgkin lymphoma[J]. Biomed, 2010,26(4):1-4. |
| [14] | Nisman B, Lafair J, Heching N , et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma[J]. Cancer, 1998,82(10):1850-1859. |
| [15] | Zhong LP, Zhu HG, Zhang CP , et al. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma[J]. Int J Oral Maxillofac Surg, 2007,36(3):230-234. |
| [16] | Rajkumar K, Ramya R, Nandhini G , et al. Salivary and serum level of CYFRA 21-1 in oral precancer and oral squamous cell carcinoma[J]. Oral Dis, 2015,21(1):90-96. |
| [17] | Hamakawa H, Bao Y, Takarada M , et al. Cytokeratin expression in squamous cell carcinoma of the lung and oral cavity: an immunohistochemical study with possible clinical relevance[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1998,85(4):438-443. |
| [18] | Feng XY, Li JH, Li JZ , et al. Serum SCCA, Cyfra 21-1, EGFR and Cyclin D1 levels in patients with oral squamous cell carcinoma[J]. Int J Biol Markers, 2010,25(2):93-98. |
| [19] | Barnett EV . Circulating immune complexes: their immunochemistry, detection, and importance[J]. Ann Intern Med, 1979,91(3):430. |
| [20] | Taneja N, Bathi R, Deka AC , et al. Evaluation of circulating immune complexes and serum immunoglobulins in oral cancer patients - A follow up study[J]. Indian J Dent Res, 2010,21(1):10. |
| [21] | Lichtenstein A, Zighelboim J, Dorey F , et al. Comparison of immune derangements in patients with different malignancies[J]. Cancer, 1980,45(8):2090-2095. |
| [22] | Scully C . Immunological abnormalities in oral carcinoma and oral keratosis[J]. J Maxillofac Surg, 1982,10:113-115. |
| [23] | Maheswari H, Eswaran MA, Srividhya S , et al. Estimation of circulating immune complexes in patients with oral leukoplakia and oral submucous fibrosis: a case control study[J]. J Clin Diagn Res, 2014,8(1):224-227. |
| [24] | Scully C, Barkas T, Boyle P , et al. Circulating immune complexes detected by binding of radiolabelled protein A in patients with oral cancer and oral premalignant lesions[J]. J Clin Lab Immunol, 1982,8(2):113-115. |
| [25] | Tiwari R, David CM, Mahesh DR , et al. Assessment of serum copper, iron and immune complexes in potentially malignant disorders and oral cancer[J]. Braz Oral Res, 2016,30(1):e101. |
| [26] | Wang J, You JL, Wang LK , et al. PTMA, a new identified autoantigen for oral submucous fibrosis, regulates oral submucous fibroblast proliferation and extracellular matrix[J]. Oncotarget, 2017,8(43):74806-74819. |
| [27] | Jayadeep A, Raveendran Pillai K, Kannan S , et al. Serum levels of copper, zinc, iron and ceruplasmin in oral leukoplakia and squamous cell carcinoma[J]. J Exp Clin Cancer Res, 1997,16(3):295-300. |
| [28] | Khanna SS, Karjodkar FR . Circulating immune complexes and trace elements (copper, iron and selenium) as markers in oral precancer and cancer: a randomised, controlled clinical trial[J]. Head Face Med, 2006,2:33. |
| [29] | Shah PH, Venkatesh R, More CB . Determination of role of ceruloplasmin in oral potentially malignant disorders and oral malignancy—a cross-sectional study[J]. Oral Dis, 2017,23(8):1066-1071. |
| [30] | Hosthor SS, Mahesh P, Priya SA , et al. Quantitative analysis of serum levels of trace elements in patients with oral submucous fibrosis and oral squamous cell carcinoma: a randomized cross-sectional study[J]. J Oral Maxillofac Pathol, 2014,18(1):46-51. |
| [31] | Ramanathan K . Oral submucous fibrosis—an alterna-tive hypojournal as to its causes[J]. Med J Malaysia, 1981,36(4):243-245. |
| [32] | Aziz NZ, Arathi K, Prasad BG , et al. Evaluation of magnesium levels in blood and saliva of oral squamous cell carcinoma and potentially malignant disorders by xylidyl blue method[J]. J Oral Maxillofac Pathol, 2018,22(1):147. |
| [33] | Wickramasinghe S, Medrano JF . Primer on genes encoding enzymes in sialic acid metabolism in mammals[J]. Biochimie, 2011,93(10):1641-1646. |
| [34] | Dhakar N, Astekar M, Jain M , et al. Total sialic acid, total protein and total sugar levels in serum and saliva of oral squamous cell carcinoma patients: a case control study[J]. Dent Res J (Isfahan), 2013,10(3):343-347. |
| [35] | Rajpura KB, Patel PS, Chawda JG , et al. Clinical significance of total and lipid bound sialic acid levels in oral pre-cancerous conditions and oral cancer[J]. J Oral Pathol Med, 2005,34(5):263-267. |
| [36] | Krishnan K , Balasundaram S. Evaluation of total and lipid bound sialic acid in serum in oral leukoplakia [J].J Clin Diagn Res, 2017,11(3):ZC25-ZC27. |
| [37] | Bose KS, Gokhale PV, Dwivedi S , et al. Quantitative evaluation and correlation of serum glycoconjugates: protein bound hexoses, sialic acid and fucose in leukoplakia, oral sub mucous fibrosis and oral cancer[J]. J Nat Sci Biol Med, 2013,4(1):122-125. |
| [38] | Sawhney H, Kumar CA . Correlation of serum bio-markers (TSA & LSA) and epithelial dysplasia in early diagnosis of oral precancer and oral cancer[J]. Cancer Biomark, 2011,10(1):43-49. |
| [39] | Parwani R, Parwani S . Quantitative evaluation of serum fucose in oral squamous cell carcinoma patients[J]. J Can Res Ther, 2011,7(2):143. |
| [40] | Rai NP, Anekar J, Shivaraja Shankara YM , et al. Comparison of serum fucose levels in leukoplakia and oral cancer patients[J]. Asian Pac J Cancer Prev, 2015,16(17):7497-7500. |
| [41] | Chinnannavar SN, Ashok L, Vidya KC , et al. Eva-luation of serum sialic acid, fucose levels and their ratio in oral squamous cell carcinoma[J]. J Int Soc Prev Community Dent, 2015,5(6):446-450. |
| [42] | Piva MR, DE Souza LB, Martins-Filho PR , et al. Role of inflammation in oral carcinogenesis (Part Ⅱ): CD8, FOXP3, TNF-α, TGF-β and NF-κB expression[J]. Oncol Lett, 2013,5(6):1909-1914. |
| [43] | Chang KP, Kao HK, Wu CC , et al. Pretreatment interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma[J]. Otolaryngol Head Neck Surg, 2013,148(5):786-791. |
| [44] | Chen Z, Malhotra PS, Thomas GR , et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer[J]. Clin Cancer Res, 1999,5(6):1369-1379. |
| [45] | Kaur J, Jacobs R . Proinflammatory cytokine levels in oral lichen planus, oral leukoplakia, and oral submucous fibrosis[J]. J Korean Assoc Oral Maxillofac Surg, 2015,41(4):171-175. |
| [46] | Aggarwal BB, Kumar A, Bharti AC . Anticancer potential of curcumin: preclinical and clinical studies[J]. Anticancer Res, 2003,23(1A):363-398. |
| [47] | Pepys MB, Hirschfield GM . C-reactive protein: a critical update[J]. J Clin Invest, 2003,111(12):1805-1812. |
| [48] | Kumar K, Kantheti LP, Reddy BV , et al. Quantitative analysis of C-reactive protein in potentially malignant disorders: a pilot study[J]. J Orofac Sci, 2015,7(1):3. |
| [49] | Bhattacharjee K, Girish HC, Sanjay M , et al. Comparison of serum C-reactive protein level in oral potentially malignant disorders and in healthy individuals[J]. Res J Pharmaceutic Biolog Chemic Sci, 2016,7(2):1285-1290. |
| [50] | Chang PY, Kuo YB, Wu TL , et al. Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer[J]. Clin Chem Lab Med, 2013,51(6):1291-1300. |
| [51] | Patel BP, Shah SV, Shukla SN , et al. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer[J]. Head Neck, 2007,29(6):564-572. |
| [52] | Lotfi A, Mohammadi G, Tavassoli A , et al. Serum levels of MMP9 and MMP2 in patients with oral squamous cell carcinoma[J]. Asian Pac J Cancer Prev, 2015,16(4):1327-1330. |
| [53] | Kayden HJ, Chow CK, Bjornson LK . Spectrophotometric method for determination of tocopherol in red blood cells[J]. J Lipid Res, 1973,14(5):533-540. |
| [54] | Lawal AO, Kolude B, Adeyemi BF , et al. Serum antioxidant vitamins and the risk of oral cancer in patients seen at a tertiary institution in Nigeria[J]. Niger J Clin Pract, 2012,15(1):30-33. |
| [55] | Bhat S, Babu S, Bhat S , et al. Status of serum and salivary ascorbic acid in oral potentially malignant disorders and oral cancer[J]. Indian J Med Paediatr Oncol, 2017,38(3):306. |
| [56] | Yu T, Liu K, Wu Y , et al. MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/β-catenin signaling pathway[J]. Oncogene, 2014,33(42):5017-5027. |
| [57] | Sun LG, Liu L, Fu HH , et al. Association of decreased expression of serum miR-9 with poor prognosis of oral squamous cell carcinoma patients[J]. Med Sci Monit, 2016,22:289-294. |
| [58] | El-Sakka H, Kujan O, Farah CS . Assessing miRNAs profile expression as a risk stratification biomarker in oral potentially malignant disorders: a systematic review[J]. Oral Oncol, 2018,77:57-82. |
| No related articles found! |